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Stem cells isolated from human amniotic fluid are
gaining attention with regard to their therapeutic po-
tential. In this work, we investigated whether these
cells contribute to tubular regeneration after experi-
mental acute kidney injury. Cells expressing stem cell
markers with multidifferentiative potential were iso-
lated from human amniotic fluid. The regenerative
potential of human amniotic fluid stem cells was com-
pared with that of bone marrow-derived human mes-
enchymal stem cells. We found that the intravenous
injection of 3.5 105 human amniotic fluid stem cells
into nonimmune-competent mice with glycerol-in-
duced acute kidney injury was followed by rapid nor-
malization of renal function compared with injection
of mesenchymal stem cells. Both stem cell types
showed enhanced tubular cell proliferation and re-
duced apoptosis. Mesenchymal stem cells were more
efficient in inducing proliferation than amniotic flu-
id-derived stem cells, which, in contrast, were more
antiapoptotic. Both cell types were found to accumu-
late within the peritubular capillaries and the inter-
stitium, but amniotic fluid stem cells were more per-
sistent than mesenchymal stem cells. In vitro
experiments demonstrated that the two cell types
produced different cytokines and growth factors, sug-
gesting that a combination of different mediators is
involved in their biological actions. These results
suggest that the amniotic fluid-derived stem cells
may improve renal regeneration in acute kidney
injury, but they are not more effective than mesen-
chymal stem cells. (Am J Pathol 2010, 177:2011–2021;
DOI: 10.2353/ajpath.2010.091245)
Stem cell-based therapy is a promising and plausible op-
tion for organ repair.1 Several groups have been successful
in demonstrating the use of different stem cell types in the
treatment of acute kidney injury (AKI) in different experimen-
tal animal models. Ex vivo expanded mesenchymal stem
cells (MSCs) or resident renal stem cells were used in these
studies.1 The advantage of MSC use in therapy is their
pluripotency, the relative ease of isolation, and the possible
ex vivo expansion of the cells.2–5 It has been shown that
MSCsmay improve the recovery from cytotoxic6,7 and isch-
emic AKI.8,9 However, the exact mechanisms that promote
kidney regeneration after stem cell injection are mostly un-
known. The process might involve recruitment of stem cells
to the site of injury, fusion of stem cells with injured cells, or
most likely paracrine/endocrine stimulation.10 In addition,
the best source of stem cells for therapeutic use remains to
be defined.
A number of studies focused on alternative sources of
stem cells with multipotential differentiating capabilities and
accessibility.11–13 Mesenchymal stem cells obtained from
the adipose tissue, the umbilical cord vein, and the dental
pulp have been investigated as a potential source for stem
cells to be used in tissue regeneration.14–17 In search for
alternative sources of stem cells, several groups have re-
ported the isolation of stem cells from human amniotic fluids
(hAFSCs) and their subsequent differentiation into all three
types of germ layer cells.18–22 Amniotic fluid (AF) supplies
the developing embryo with nutrients and provides me-
chanical protection. AF contains cells of embryonic origin,
and it is indeed used in routine prenatal diagnosis to test for
chromosomal aberrations of the embryo.
Perin et al23 injected hAFSCs into murine embryonic kid-
neys and tested their contribution to the early renal devel-
opment. They found that hAFSCs differentiated into renal
vesicles and comma- and s-shaped bodies.
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Because the retrieval of hAFSCs is considered ethi-
cally acceptable and does not involve the destruction of
human embryos, stem cells from amniotic fluid present
an attractive alternative to embryonic stem cells.24–27 A
further finding that is making stem cells from AF a very
attractive source for therapeutic use is the absence of
teratoma formation when these cells are injected in vivo.23
The aim of the present study was to investigate
whether hAFSCs may contribute to tubular regeneration
in AKI induced by glycerol injection in non-immune-com-
petent SCID mice. In addition, we aimed to compare the
regenerative potential of hAFSCs with that of human bone
marrow-derived MSCs.
Materials and Methods
Isolation and Culture of hAFSCs
hAFSCs were isolated as reported recently.28 AF samples
were collected from 38 women (median age: 37 years)
undergoing amniocentesis for routine prenatal diagnosis at
14 to 17 weeks of pregnancy with informed written consent
and approval of the local ethics committee. The cellular
content of the AF samples (5–10 ml) was pelleted by cen-
trifugation (1200 rpm, room temperature) and washed in
PBS. The resulting pellet was resuspended in -minimal
essential medium (Lonza, Basel, Switzerland) containing
20% Amniomax (Gibco, Carlsbad, CA)  10% fetal calf
serum (Euroclone, Wetherby, UK) 100g/ml glutamine
100 IU/ml penicillin/streptomycin (all from Sigma-Aldrich, St.
Louis, MO), plated in 25-cm2 T-flasks and maintained at
37°C with a 5% CO2 atmosphere. After 5 to 7 days, nonad-
herent cells were removed, and the adherent cells were
refed every 3 to 4 days and grown until they reached
confluence. To expand the isolated cells, the adherent
semiconfluent monolayer was detached with nonenzymatic
solution (Sigma-Aldrich) and expanded for several pas-
sages until they no longer reached confluence.
Isolation and Culture of Bone Marrow-Derived
Mesenchymal Stem Cells
Bonemarrow cells were harvested from healthy donors with
informed consent obtained in accordance with the Decla-
ration of Helsinki. Bone marrow-derived MSCs were iso-
lated, cultured, and characterized as described earlier.29 In
brief, bone marrow cells were layered on a Ficoll gradient
(density 1022 g/ml; Sigma-Aldrich) and centrifuged at 1500
rpm for 30 minutes. The mononucleated cells were cultured
in the presence of mesenchymal stem cell basal medium
(Lonza). After 5 days of culture, the medium was changed.
To expand the isolated cells, the adherent monolayer was
detached by trypsin treatment for 5 minutes at 37°C, after
15 days for the first passage and every 7 days for succes-
sive passages. Cells were seeded at a density of 1  104
cells/cm2 and used within passage 6.
At each passage, cells were counted and analyzed for
immunophenotype by cytofluorimetric analysis and immu-
nofluorescence. All of the MSC preparations at different
passages of culture expressed the typical MSC markers:
CD105, CD73, CD44, CD90, and CD166. They also ex-
pressed HLA class I. MSC preparations did not express
hematopoietic markers (CD45, CD14, and CD34) and the
costimulatory molecules (CD80, CD86, and CD40). The
adipogenic, osteogenic, and chondrogenic differentiation
abilities of MSCs were determined.
Cytofluorimetric Analysis of hAFSCs
Cytofluorimetric analysis was performed as described pre-
viously.30,31 Fluorescein isothiocyanate- and phycoerythrin-
conjugated antibodies with specificities against CD44,
CD45, CD90, CD105 (AbD Serotec, Raleigh, NC), CD73,
CD166 (BD Pharmingen, San Diego, CA), Oct3/4, and
SSEA4 (R&D Systems, Minneapolis, MN) were used. Non-
immune isotypic IgG antibodies conjugated to fluorescein
isothiocyanate and phycoerythrin were used as controls
(Dako Cytomation, Copenhagen, Denmark). For each stain-
ing, approximately 100,000 cells were incubated for 20
minutes with a particular antibody (as listed above), washed
with PBS, and analyzed on FACSCalibur (Becton Dickinson,
Franklin Lakes, NJ) using CellQuest Pro 5.2.1 software.
PCR
To confirm the cytofluorimetric analysis of nuclear markers
(Oct4, SSEA4, and vimentin), we performed real-time PCR.
In brief, total RNA was isolated with the TRIzol method
(Invitrogen, Carlsbad, CA) and transcribed into cDNA using
a High-Capacity cDNA RT Kit (Applied Biosystems, Foster
City, CA). Primers for Oct4, SSEA4, and vimentin were
designed using Primer Express (Applied Biosystems) and
synthesized from Invitrogen (Carlsbad, CA) as previously
described.28 Quantitative real-time PCR was performed us-
ing a Step One Sequence Detection system according to
TaqMan protocols (Applied Biosystems). The SYBR ®
Green detection method was used to detect the amplifica-
tion rate of the targets. Reactions were set up using the
TaqMan Universal PCR MasterMix (2) (Applied Biosys-
tems). Each target was measured in triplicate using 48-well
plates. Relative expression of mRNAs was compared using
the relative Ct quantification method.
Differentiation Potential Assay
To assess the differentiation potential, AF-derived adherent
cells were cultured in osteogenic, adipogenic, chondro-
Figure 1. Experimental schedule. Schematic representation of the protocol of
glycerol-induced AKI and treatment with either hAFSCs or MSCs. Glycerol was
injected intramuscularly at time 0. The arrow at day three indicates the administra-
tion of 350,000 cells or vehicle alone; the subsequent arrows indicate the time of
sacrifice.
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genic, and neurogenic medium according to the manu-
facturer’s instructions (Lonza). Osteogenic differentiation
was demonstrated by detection of the intracellular hy-
droxyapatite accumulation by Von Kossa staining, after
incubation of the cells over a period of 21 days in osteo-
genic differentiation media. Adipogenic differentiation
was performed by incubation in adipogenic induction
and maintenance medium (alternated every 3 to 4 days).
Oil Red O staining was used to assess the presence of
intracellular lipid vesicles, which were visible after 2 to 3
weeks in culture. For chondrogenic differentiation, cells
were grown as freely floating pelleted aggregate kept in
suspension culture for 2 to 3 weeks in the presence of
transforming growth factor-3. The pellet was included in
paraffin and stained with Alcian Blue to identify the pres-
ence of hyaluronic acid and sialomucin.
Cytokine Assay
Tomeasure the cytokines produced by hAFSCs andMSCs,
we performed a multiplex cytokine array, based on fluores-
cently dyed microspheres (Bio-Plex, Bio-Rad Laboratories,
Hercules, CA). hAFSCs and MSCs were cultured to a con-
fluence of 90%. Cells were then exposed to -minimal es-
sential medium with 0.5% albumin (Sigma-Aldrich) for 12
hours. The superantant (conditioned medium) was col-
lected, centrifuged (1200rpm, 4°C, 5 minutes) to remove
cellular debris and frozen at 20°C. The cytokine assay
was performed for five different isolated hAFSCs andMSCs.
Figure 2. Fluorescence-activated cell sorter analysis of hAFSCs. Represen-
tative fluorescence-activated cell sorter analyses for the expression of surface
markers CD44, CD45, CD73, CD90, CD 105, CD166, and SSEA4 and the
intracellular transcription factor Oct4. The gray line indicates the isotypic
controls. All analyzed hAFSCs (n  12) showed similar results in passages 2
to 5. PE, phycoerythrin; FITC, fluorescein isothiocyanate.
Figure 3. Differentiation characteristics of hAFSCs. A: Representative of
osteogenic differentiation detected as calcium oxalate deposits detectable by
Van Kossa staining. B: Representative of adipogenic differentiation visualized
by Oil Red O staining of the intracellular lipid vesicles. C: Representative of
chondrogenic differentiation detected by Alcian Blue staining. Micrographs
are representative of 12 experiments.
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Cell Proliferation Assay
Tubular epithelial cells (TECs) were prepared and charac-
terized as described previously.29 The cells were seeded at
4000 cells/well into 96-well plates in Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich), deprived of fetal calf se-
rum incubated with or without 3 g/ml of human leukemia
inhibitory factor (LIF) blocking antibody (R&D Systems) in
the presence of 30% conditioned medium from hAFSCs or
MSCs. DNA synthesis was detected as incorporation of
5-bromo-2-deoxyuridine (BrdU) into the cellular DNA after
48 hours of culture. Cells were then fixed with 0.5 mol/L
ethanol-HCl and incubated with nuclease to digest the
DNA. BrdU incorporated into the DNA was detected using
an anti-BrdU peroxidase-conjugated antibody and visual-
ized with a soluble chromogenic substrate (Roche Applied
Science, Mannheim, Germany). Optical density was mea-
sured with an ELISA reader at 405 nm.
Acute Renal Injury in SCID Mice and Treatment
Rhabdomyolyses was induced in a total of 75 male SCID
BALB/c mice (Charles River, Milano, Italy) as described
before.6,32,33 In brief, animals (body weight 23  6 g) were
anesthetized and injected with glycerol into the left and right
hind femoral muscles. Animals received 8 l of 50% glyc-
erol/g b.wt. Three days after induction of experimental in-
jury, animals were injected with 350,000 hAFSCs or MSCs
(Figure 1). For in vivo detection of proliferating cells, mice
were injected intraperitoneally with 2 mg of BrdU 24 and 48
hours before biopsy samples were harvested. Animals were
sacrificed as follows: day 3 (n  6), day 5 (CTRL n  8,
hAFSC n 8, and MSC n 8), day 8 (CTRL n 6, hAFSC
n  9, and MSC n  8), and day 21 (CTRL n  8, hAFSC
n  8, and MSC n  6). Kidney tissue was fixed in 10%
formaldehyde or frozen in OCT (Tissue-Tek, Sakura Fi-
neTek, Torrance, CA). Studies were approved and per-
formed in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.34
Biochemical Data
To assess renal function, serum was collected at the time of
sacrifice. Serum creatinine was measured using a colori-
metric microplate assay based on the Jaffe reaction (Quan-
tichrom Creatinine Assay, BioAssay Systems, Hayward,
CA) from blood collected at days 0, 3, 5, 9, and 15. Serum
was isolated from the supernatant by centrifugation of blood
samples (3000 rpm, 5 minutes). Blood urea nitrogen (BUN)
was measured by direct quantification of serum urea with a
colorimetric assay kit according to the instruction protocol
(Quantichrom Urea Assay, BioAssay Systems).
Renal Morphology
To evaluate renal histology, paraffin-fixed biopsy samples
were sectioned (5 m) and stained with H&E (Merck, Darm-
stadt, Germany). To compare the changes in renal histol-
ogy, luminal hyaline casts and necrosis were assessed in
25 nonoverlapping high-power fields (40). The quantifi-
cation of casts and tubular profiles showing necrotic cells
was recorded in a single-blinded fashion. To detect prolif-
erating tubular cells, immunohistochemical analysis was
performed as described earlier (T.W. Kirkman: Statistics to
Use, http://www.physics.csbsju.edu/stats, last accessed
September 2, 2009). In brief, kidney sections were boiled in
citrate buffer for 10 minutes to unmask antigens and sub-
sequently blocked with 5% bovine serum albumin in PBS.
Kidney tissue was stained with a monoclonal anti-proliferat-
ing cell nuclear antigen (Pcna) antibody (1:400, Santa Cruz
Biotechnology, Santa Cruz, CA) monoclonal anti-BrdU an-
tibody (1:25, Dako Cytomation, Dako, Milano, Italy). An anti-
mouse horseradish peroxidase-conjugated antibody
(1:300, Pierce, Rockford, IL) was used for immunoperoxi-
dase stainhigh-powering. Pcna- and BrdU-positive cell
quantification was performed by counting positive nuclei
per field (40) in 20 kidney sections that were chosen
randomly from the kidney cortex.
Tubular Apoptosis
To quantify tubular apoptosis at day 5 after injury, paraffin-
fixed tissue from five animals per group (hAFSC- or MSC-
injected and untreated controls) was stained by terminal
deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) using the ApopTaq Apoptosis Detection Kit (Milli-
pore Corporation, Billerica, MA) according the manufactur-
er’s protocol.
Figure 4. Evaluation of renal function. Changes
in renal function were measured by BUN (A) and
creatinine (B). Glycerol injection resulted in ele-
vated BUN levels starting at day three. In animals
injected with hAFSCs or MSCs, BUN normalized
48 hours after injection and remained close to
baseline throughout the experiment (A). Similar
results were obtained measuring creatinine levels
(B). Analysis of variance was performed: *P 	
0.05, stem cells treated versus untreated.
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Identification of CFSE-Labeled Human MSCs or
hAFSCs
To study intrarenal localization and to quantify localized
human MSCs or hAFSCs, cells were labeled with a Vy-
brant CFDA SE Cell Tracer Kit (CFSE) (Molecular Probes,
Leiden, The Netherlands) and subsequently injected in
glycerol-treated mice (n  3 per experimental groups).
After 1, 2, and 5 days from cell injection, mice were
sacrificed, and kidney samples were embedded in OCT
and snap-frozen in liquid nitrogen. Tissue sections (5 m)
were fixed in acetone (10 minutes) and double-stained
with an anti-fluorescein/Oregon Green polyclonal anti-
body (Molecular Probes) (detects cells labeled with
CFSE) and with anti-cytokeratin monoclonal antibody (Im-
munological Sciences, Rome, Italy), used to better iden-
tify tubular structures. Alexa Fluor 488 goat anti-rabbit
IgG and Texas Red anti-goat IgG (all from Molecular
Probes) were used as secondary antibody. Confocal mi-
croscopy analysis was performed using a Zeiss LSM 5
Pascal model confocal microscope (Carl Zeiss Interna-
tional, Oberkochen, Germany). Hoechst 33258 dye (Sig-
Figure 5. Histology of AKI in hAFSC- or MSC-treated and control untreated mice. A and B: Representative
micrographs of renal tissue from mice on day 3 (A) and day 5 (B) after glycerol injection, showing tubular
necrosis, tubular protein casts, and loss of brush border; vacuolization of the epithelial cells of the proximal
tubules is visible in the high power images. C andD: Representative micrographs of renal tissue frommice on
day 5 after glycerol injection treated with hAFSCs (C) or MSCs (D), showing signs of recovery of tissue injury.
E–G: Representative micrographs of renal tissue from mice on day 8 after glycerol injection, showing the
persistence of renal injury in untreated animals (E) and signs of recovery in hAFSC-treated (F) or MSC-treated
(G) animals. H–J: Representative micrographs of renal tissue from mice on day 21 showing the normal
morphology of tissue in animals untreated (H) or treated with hAFSCs (I) and MSCs (J). Original magnification
of each panel: 200 (left); 400 (right).
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ma-Aldrich) was added for nuclear staining. To confirm
the human origin of MSCs or hAFSCs, kidney sections of
mice injected with CFSE-labeled cells were stained with
HLA class I polyclonal antibody (Santa Cruz Biotechnol-
ogy). Scoring for CFSE-positive or HLA-positive cells was
performed by counting the number of positive cells per
field in 10 randomly chosen sections of kidney cortex of
three mice per group using 40 magnification. Data are
expressed as number of CFSE-positive or HLA-positive
cells per high-power field (hpf).
Statistical Analysis
Results are generally expressed as mean  SEM. Statis-
tical significance was defined as P 	 0.05; tests were
performed by using Microsoft Excel. Analysis of variance
(P 	 0.05) was performed to compare differences of the
biochemical data, tubular proliferation, and renal mor-
phology.35 One-way analysis of variance followed by
Dunnett’s or the Newman-Keuls multicomparison test or
t-test was performed using XLSTAT 2009 (Addinsoft Inc.,
New York, NY).
Results
Isolation and Characterization of hAFSCs
hAFSCs were obtained as described previously28 and
were characterized on the basis of their phenotype and
their differentiating capabilities. Cytofluorimetric analysis
showed that cells were uniformly positive for surface
markers CD44, CD73, CD105, and CD166, typically ex-
pressed by mesenchymal stem cells. At early passa-
ges,4–7 cells were also positive for the surface marker
SSEA4 (a human embryonic stage-specific marker) and
partially for Oct4 (
21%), a stem cell marker of pluripo-
tency.36 hAFSCs were negative for CD45, a marker of the
hematopoietic lineage cells and fibroblasts. At variance
with bone marrow-derived MSCs, CD90 was negative. A
representative fluorescence-activated cell sorter analysis
of hAFSCs is shown in Figure 2. Expression of Nanog-1
and Oct-4 was detected in all cultures by real-time PCR
(data not shown). hAFSCs were negative for SSEA1,
SSEA3, CD133, and NCAM (data not shown). This phe-
notype was similar to that described previously.28
Using appropriate differentiation media, we were able
to differentiate hAFSCs into chondrocytes, adipocytes,
and osteocytes. As shown in Figure 3, hAFSCs showed
calcium oxalate precipitates after osteogenic differentia-
tion (Figure 3A) and intracellular lipid vesicles by Oil Red
O staining after adipogenic induction (Figure 3B). Chon-
drogenic differentiation was demonstrated by Alcian Blue
staining of the pelleted hAFSCs, visualizing the expres-
sion of hyaluronic acid and sialomucin (Figure 3C).
Effect of hAFSC on the Recovery of
Glycerol-Induced AKI in SCID Mice and
Comparison with MSCs
To investigate whether hAFSCs have a beneficial effect
on the regeneration after AKI, experimental AKI was in-
duced by injection of glycerol, as described before.6
Intramuscular injection of glycerol causes rhabdomyoly-
ses of the muscular tissue, thereby releasing large quan-
tities of enzymes, hemoglobin, and myoglobin to the kid-
ney. Exposure of the kidney to myoglobin and iron is
followed by tubular injury. After the glycerol injection
serum creatinine and BUN levels increased, peaking af-
ter 72 hours, and remained elevated over the course of
10 days and normalized on day 21. Three days after
induction of AKI, mice received 3.5  105 hAFSCs or
MSCs in 150 l of PBS intravenously via the tail vein.
Control animals received PBS instead. The experimental
time line is shown in Figure 1. Animals were sacrificed at
days 5, 8, and 21 after the induction of AKI.
Mice injected with hAFSCs exhibited significantly re-
duced BUN from day 5 (48 hours after treatment),
throughout the experiment (Figure 4A), with respect to
that in animals treated with vehicle alone. In addition,
treatment with hAFSCs resulted in the normalization of the
creatinine levels as soon as day 5 (Figure 4B). The func-
tional recovery obtained with hAFSCs was similar to that
obtained by infusion of MSCs (Figure 4, A and B).
Histological analysis of the kidneys of glycerol-injected
animals on day 3 after injury showed epithelial injury
characterized by tubular necrosis and vacuolization of
tubular epithelial cells. In addition, proximal tubular cells
showed a loss of brush border and intratubular protein
casts (Figure 5A). Mice treated with hAFSCs or MSCs
showed a marked reduction of tissue damage with re-
spect to that in untreated controls. On day 5 after glycerol
injection (48 hours after stem cell injection) animals
treated with hAFSCs (Figure 5C) or MSCs (Figure 5D)
exhibited reduced tissue damage, compared with that in
untreated control animals (Figure 5B). At day 8, an almost
normal renal structure was observed in mice treated with
hAFSCs or with MSCs (Figure 5, F and G) compared with
Table 1. Effects of hAFSCs and MSCs on Renal Morphology and Tubular Apoptosis
Control AKI  hAFSCs AKI  MSCs AKI
Casts (n/hpf) 0 0.36  1.01* 0.54  0.17† 5.05  7.54
Necrosis (n/hpf) 0 0.81  1.38* 0.3  0.14† 3.85  4.44
TUNEL-positive cells (n/hpf) 0 3.2  0.8* 7.8  2.2† 21.7  16.9
Comparison of hAFSC or MSC injection on tubular morphology and apoptosis at day 5 after AKI induction. Numbers in the table represent the
mean  SD of tubular casts and necrotic tubules and of apoptotic cells detected by TUNEL, observed under high power (magnification, 400).
*P 	 0.05 for hAFSC injection versus untreated AKI.
†P 	 0.05 for MSC injection versus untreated AKI.
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that in untreated animals (Figure 5E). Normal histology
was restored in all of the experimental groups on day 21
(Figure 5, H–J).
In Table 1, the morphometric evaluation of injury in
mice with AKI injected or not with hAFSCs or MSCs was
compared. Stem cell-injected animals had a significantly
lower number of cast-containing tubules and a lower
number of necrotic tubules compared with untreated an-
imals with AKI. No significant difference was observed
between animals treated with hAFSCs or MSCs.
Effect of hAFSCs on Tubular Cell Proliferation
and Apoptosis after AKI and Comparison
with MSCs
To assess the regenerative response of kidney tissue in
hAFSC-injected animals, we quantified the proliferation of
tubular cells by counting BrdU- and Pcna-positive cells
(Figure 6). Proliferation of tubular cells was significantly
increased in the stem cell-treated animals with respect to
that in untreated controls. In hAFSC-injected mice prolif-
eration at days 5 was slightly increased but not signifi-
cantly, whereas at day 8 proliferation was significantly
increased compared with that in controls (Figure 6, A-C).
MSC treatment induced significantly increased prolifera-
tion of tubular epithelial cells both at day 5 and 8. Com-
paring proliferation induced by hAFSCs and MSCs, we
observed an overall greater proliferation in animals
treated with MSCs than in those treated with hAFSCs,
which was significant at day 5 (Figure 6, A and B). On day
21, animals treated with hAFSC showed sustained tubu-
lar proliferation, which was completely absent in animals
treated with MSCs (Figure 6, A and B).
Quantification of apoptotic tubular cells by TUNEL in
tissues retrieved from animals on day 5 after AKI
showed a significant reduction of apoptosis in hAFSC-
and MSC-injected animals compared with that in un-
treated control animals (Table 1). However, the anti-
apoptotic effect of hAFSCs was significantly greater
than that of MSCs.
hAFSC and MSC Renal Localization in Mice
with AKI
To evaluate the engraftment of hAFSCs and of MSCs in
the kidneys of mice with AKI, stem cells were labeled with
the CFSE Cell Tracer Kit before their in vivo infusion. In
renal tissues of glycerol-treated mice injected with CFSE-
positive cells, 7.9  1.5 hAFSCs/hpf and 8.7  1 MSCs/
hpf were detected at day 4, 1 day after cell injection
(Figure 7, A and C). CFSE-positive cells were seen mainly
in peritubular capillaries (Figure 7C). At day 5 of AKI (2
days after cell injection), 8  1.7 CFSE-positive hAFSCs
were detected in peritubular capillaries and in the inter-
stitium. In contrast, MSCs were significantly decreased
(1.6  0.25) at this time point (Figure 7A). Moreover,
CFSE-positive hAFSCs persisted to be significantly ele-
vated at day 8 in the renal interstitium of AKI mice (4.6 
0.95 CFSE-positive cells), whereas CFSE-positive MSCs
were almost absent (Figure 7, A and C). The human origin
of CFSE-positive cells was confirmed in kidney sections
stained for human HLA-I antigen (Figure 7, B and C), and
the amount of cells detected by HLA immunostaining was
comparable with that detected by counting CFSE-posi-
tive cells. With use of HLA staining, hAFSCs were detect-
able also at day 21, whereas MSCs were completely
absent (Figure 7, B and C). There were no signals de-
tected in CFSE-labeled or HLA-positive cells within the
kidneys of control mice (Figure 7D).
Figure 6. Tubular proliferation in AKI untreated or treated with hAFSCs
or MSCs. A and B: Graphs illustrating the quantification of BrdU (A)- and
Pcna (B)-positive cells at days 5, 8, and 21 in AKI mice treated with
hAFSCs or MSCs or injected with saline as a control. Statistical significance
was calculated using analysis of variance with the Newman-Keuls multi-
comparison test: *P 	 0.05, stem cells in AKI-treated versus untreated
mice; **P 	 0.005, MSCs versus hAFSCs. C: Representative micrographs
showing BrdU- and Pcna-positive cells in kidney tissue from AKI mice
injected with saline or hAFSCs at day eight. Original magnification, 400.
Ctrl, control.
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Comparison of Grow Factors and Cytokines
Produced by Cultured hAFSCs and MSCs
To investigate the possible differential mechanism of re-
pair induced by hAFSCs and MSCs, we investigated the
secretion of cytokines involved in tissue repair by a mul-
tiplex cytokine assay (Figure 8A). Both cell types re-
leased high levels of vascular endothelial growth factor.
The main difference in cytokine/growth factors produced
by hAFSCs and MSCs were a higher release of hepato-
cyte growth factor and stromal derived factor-1 by MSCs
with respect to hAFSCs and a higher release of LIF by
hAFSCs with respect to MSCs. To evaluate whether the
enhanced production of LIF may account for the biolog-
ical activity of hAFSCs, we tested the effect of LIF block-
ade on TEC proliferation induced by the conditioned
medium. Incubation of TECs with hAFSC- or MSC-de-
rived conditioned medium promoted cell proliferation
compared with that of control cells incubated with vehicle
only (Figure 8B). When TECs were incubated with condi-
tioned medium in the presence of LIF-blocking antibody,
we observed a 
50% decrease in proliferation of cells
stimulated with hAFSC-derived conditioned medium. No
effect was found with cells stimulated with MSC-derived
conditioned medium.
Discussion
Amniotic fluid contains stem cells from the fetus, and it
has been suggested that they could represent an ethi-
cally unproblematic alternative to embryonic stem cells
Figure 7. Detection of hAFSCs or MSCs within the kidneys of AKI mice by CFSE or HLA immunostaining. A and B: Graphs illustrating the quantification of
CFSE-labeled cells (A) and of HLA-positive cells (B). Student’s t-test was performed between hAFSC- and MSC-treated AKI mice at each time point. *P 	 0.001.
C: Representative confocal micrographs showing the presence of MSCs or hAFSCs within the kidneys of mice with AKI at days 4, 8, and 21. Tubular epithelial
cells were stained for cytokeratin (red). The CFSE-labeled and HLA-positive cells were detected as green fluorescence. Nuclei were counterstained with
4,6-diamidino-2-phenylindole (blue).D: Representative confocal micrographs showing the absence of detection of CFSE-labeled or HLA-positive cells within the
kidneys of control mice (Ctrl). Original magnification, 400.
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for stem cell therapy.24,37 The results of the present study
demonstrated that stem cells isolated from human amni-
otic fluid accelerate the recovery of murine experimental
AKI similarly to MSCs. Treatment with hAFSCs improved
renal function and increased the proliferative response in
the tubular compartment of the kidney. However, when
the effect of hAFSCs was compared with that of MSCs,
despite a partial difference in growth factor production,
a substantial overlap on the recovery from AKI was
observed.
Extensive studies have been performed to investigate
the role and potential of stem cells in AKI. Most of the
research focused on bone marrow-derived stem cells
(BMSCs) and in vitro expanded MSCs, which were ap-
plied to different mouse models of AKI.
By transplanting bone marrow to animals with sub-
sequent induction of AKI, several groups were able to
demonstrate the contribution of BMSCs in the regen-
eration after tubular injury.38–41 It has been suggested
that BMSCs are recruited to the site of injury and
contribute to regeneration.42 Whether BMSCs are able
to trans-differentiate into tubular epithelial cells is still
disputed.8,9
Much emphasis has been put on exogenous adminis-
tration of MSCs, because of their greater therapeutic
potential. MSCs can be differentiated into all renal cell
types, as shown by injecting MSCs into a mouse whole-
embryo culture.43 When injected into mice with cisplatin- or
glycerol-induced AKI, MSC have been shown to acceler-
ate the recovery.6,7,32 Moreover, MSCs also protected
from ischemia-related AKI by differentiation-independent
mechanisms.8,9,44 It has been suggested that the bene-
ficial effect of BMSCs or exogenous MSCs is due to
transient localization to the damaged renal structures.
Lange et al44 injected MSCs labeled with iron-dextran
particles into rats and detected MSCs in the kidney cor-
tex of animals with ischemia-reperfusion injury and not
in the healthy controls. In their study, labeled MSCs
were predominantly found in the glomerular capillaries,
whereas To¨gel et al,9 using two-photon laser confocal
microscopy, found MSCs to be localized in the glomeru-
lar and the peritubular capillaries of rats with ischemia-
reperfusion injury.9 MSCs were also found to localize to
the peritubular capillaries and further migrate to the tu-
bular interstitium.32 The low number of MSCs that were
found to engraft within the injured kidney suggests that
MSCs exhibit a trophic effect on the injured tissue,
thereby promoting the repopulation of the damaged tu-
bular structures.
In the present study, we found that intravenous injec-
tion of hAFSCs accelerated the recovery of glycerol-
induced AKI. Moreover, we compared this effect with that
of MSCs. hAFSCs promoted histological and functional
amelioration of renal damage comparable to that of
MSCs. Moreover, both types of stem cells stimulated
proliferation of tubular epithelial cells. However, the quan-
tification of proliferating tubular cells by counting BrdU-
or Pcna-positive cells revealed that the kinetics of prolif-
eration induced by MSCs and hAFSCs was different.
MSCs promoted an early tubular proliferation, whereas
proliferation induced by hAFSCs was delayed and per-
sisted up to 21 days after injury. In addition, hAFSCs
exerted a pronounced antiapoptotic action on tubular
cells, whereas MSCs were less effective.
We tried to explain the differences in the protective
mechanisms observed for hAFSCs and MSCs by inves-
tigating the renal localization kinetics in vivo and the pro-
duction of different soluble factors in vitro. hAFSCs per-
sisted significantly longer within the renal tissue than
MSCs. We found that neither hAFSCs or MSCs integrated
into the renal tissue but rather remained localized into the
interstitium. A similar result was reported previously by
several authors for MSCs.35,42,44 The peritubular localiza-
tion of stem cells suggests that the mechanism of tissue
repair for both cell types is dependent on the local re-
lease of soluble factors rather than on tissue integration.
These results differ from the recent study of Perin et al,45
who showed that 1  106 hAFSCs injected directly into
the renal tissue of nu/nu mice with AKI are able to differ-
entiate into cells expressing both adult proximal and
distal tubular markers, thus contributing to renal regen-
eration. This discrepancy may depend on the amount of
cells administered and on the modality of administration.
Figure 8. Cytokines/growth factors released into the conditioned medium
of hAFSCs and MSCs and effects on tubular cell proliferation. A: Evaluation
of cytokines/growth factors released into the conditioned medium of 1 106
hAFSCs and MSCs after a 12-hour incubation in RPMI 1640 plus 0.5% bovine
serum albumin. Cytokines were measured using a multiplex cytokine array.
Data represent the mean  SD of five different cell lines. FGF, fibroblast
growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endo-
thelial growth factor; LIF, leukemia inhibitory factor; NGF, nerve growth
factor; SCF, stem cell factor; SDF, stromal derived factor; HGF, hepatocyte
growth factor. B: Proliferation of TECs induced by the conditioned medium
(CM) of hAFSCs and MSCs was evaluated by incorporation of BrdU and
expressed as the percent increase over unstimulated control cells (Ctrl). The
role of LIF in proliferation induced by the conditioned medium was evalu-
ated using 3 g/ml anti-LIF blocking antibodies (Ab-LIF). Data represent the
mean  SD of three different experiments performed in duplicate. Analysis
of variance with Dunnett’s comparison test: *P 	 0.005, CM plus Ab-LIF
versus CM alone.
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Analysis of cytokines and growth factors released by
hAFSCs and MSCs into the conditioned medium revealed
differences in the combination of the factors produced. In
particular, hAFSCs produced less hepatocyte growth
factor and stromal derived factor-1 than MSCs but more
LIF. LIF has been shown to be an important factor in renal
development as well as in the repair of the adult renal
tissue after AKI.46 The different combination of growth
factors may be the cause for the differences in prolifera-
tion and apoptosis of TEC after treatment with stem cells.
Experiments of LIF blockade in the hAFSC conditioned
medium indicate a potential critical contribution of this
factor, as it significantly reduced proliferation of TECs
stimulated with hAFSC conditioned medium.
Proliferation of resident epithelial cells is indeed con-
sidered the main repair mechanism, because it has been
shown by genetic fate-mapping techniques in a model of
ischemic tubular injury.47,48 The rapid postinjury onset of
regenerative tubular growth could depend on the high
number of proximal tubular cells found in the G1 phase in
tubules.49
The paracrine/endocrine role of stem cells is sup-
ported by the evidence that MSC culturing media alone
had a positive effect on regeneration after renal injury35
and by the finding that even adult stem cells from devel-
opmentally distant organs such as the brain hold the
potential to contribute to renal regeneration.50 We re-
cently found that the release of microvesicles and the
transfer of genetic information may account for the ben-
eficial effect of MSCs in the recovery of experimental AKI,
further supporting a paracrine action.29
In conclusion, hAFSCs may provide an alternative
source of stem cells for the treatment of AKI. However,
although the mechanisms involved may be partially dif-
ferent, the efficacy of hAFSCs is not greater than that of
MSCs, which represent a more accessible source of
adult stem cells. Further studies in different models of AKI
are needed to define the most suitable type of stem cell
to be used in stem cell therapy of AKI.
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